The subgroup analysis of patients with advanced NSCLC (Tumor stage III-IV) showed that, NSCLC patients with p53 negative expression were more sensitive to platinum chemotherapy than those with p53 positive expression, the pooled OR = 1.93 (95%CI: 1.27∼2.93, P < .01). Here, TP53 is linked to neoplasm.